Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) (EXIST-2)
This study has been completed.
First Posted: November 13, 2008
Last Update Posted: February 17, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )